• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with "Spanish Flu"?与“西班牙流感”相比,诊断方法、治疗手段和疫苗对新冠疫情演变产生了影响吗?
Pathogens. 2023 Jun 23;12(7):868. doi: 10.3390/pathogens12070868.
2
Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics.通过基于细胞的再生医学抗击 COVID-19 之战:从 1918 年西班牙流感和其他先前的大流行中吸取的教训。
Stem Cell Rev Rep. 2021 Feb;17(1):9-32. doi: 10.1007/s12015-020-10026-5.
3
May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?1918 年流感大流行的分析能否为想象 2019 年冠状病毒病(COVID-19)的可能规模提供线索?
J Transl Med. 2020 Dec 22;18(1):489. doi: 10.1186/s12967-020-02673-6.
4
The beginning and ending of a respiratory viral pandemic-lessons from the Spanish flu.呼吸道病毒大流行的始末——以西班牙流感为例。
Microb Biotechnol. 2022 May;15(5):1301-1317. doi: 10.1111/1751-7915.14053. Epub 2022 Mar 22.
5
COVID-19 and Spanish flu-18: review of medical and social parallelisms between two global pandemics.COVID-19 和西班牙流感-18:对两次全球大流行的医学和社会相似性的回顾。
J Prev Med Hyg. 2021 Sep 15;62(3):E613-E620. doi: 10.15167/2421-4248/jpmh2021.62.3.2124. eCollection 2021 Sep.
6
Lessons should be learned: Why did we not learn from the Spanish flu?我们应该吸取教训:为什么我们没有从西班牙流感中吸取教训?
SAGE Open Med. 2024 May 29;12:20503121241256820. doi: 10.1177/20503121241256820. eCollection 2024.
7
The Spanish flu.西班牙流感。
Presse Med. 2022 Sep;51(3):104127. doi: 10.1016/j.lpm.2022.104127. Epub 2022 Jun 1.
8
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗:全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
9
Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting.从西班牙流感到 COVID-19 的一个世纪呼吸道传染病的叙述性回顾,以及纳米技术对 COVID-19 诊断和免疫系统增强的影响。
Virol J. 2022 Oct 24;19(1):167. doi: 10.1186/s12985-022-01902-2.
10
The enigma of the 1889 Russian flu pandemic: A coronavirus?1889 年俄罗斯流感大流行之谜:一种冠状病毒?
Presse Med. 2022 Sep;51(3):104111. doi: 10.1016/j.lpm.2022.104111. Epub 2022 Feb 4.

引用本文的文献

1
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.针对新冠病毒的信使核糖核酸疫苗作为其他人类传染病的开拓者
Vaccines (Basel). 2024 Dec 16;12(12):1418. doi: 10.3390/vaccines12121418.
2
Power spectral density and similarity analysis of COVID-19 mortality waves across countries.各国新冠疫情死亡波动的功率谱密度与相似性分析
Heliyon. 2024 Jul 31;10(15):e35546. doi: 10.1016/j.heliyon.2024.e35546. eCollection 2024 Aug 15.
3
Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.默克尔细胞癌疫苗的当前进展:叙述性综述与更新
Vaccines (Basel). 2024 May 13;12(5):533. doi: 10.3390/vaccines12050533.
4
COVID-19 post-pandemic reflections from sub-Saharan Africa: what we know now that we wish we knew then.撒哈拉以南非洲地区对新冠疫情大流行后的反思:我们现在所知道的,是当时希望自己能知道的。
Public Health Pract (Oxf). 2024 Feb 29;7:100486. doi: 10.1016/j.puhip.2024.100486. eCollection 2024 Jun.

本文引用的文献

1
Evolution of antibody immunity following Omicron BA.1 breakthrough infection.奥密克戎 BA.1 突破感染后抗体免疫的演变。
Nat Commun. 2023 May 12;14(1):2751. doi: 10.1038/s41467-023-38345-4.
2
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.新冠病毒奥密克戎变异株加强免疫可诱导人体产生新的 B 细胞反应。
Nature. 2023 May;617(7961):592-598. doi: 10.1038/s41586-023-06025-4. Epub 2023 Apr 3.
3
An mRNA Influenza Vaccine - Could It Deliver?一种mRNA流感疫苗——它能成功吗?
N Engl J Med. 2023 Mar 23;388(12):1139-1141. doi: 10.1056/NEJMcibr2215281.
4
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.既往 SARS-CoV-2 感染对再感染的保护作用:系统评价和荟萃分析。
Lancet. 2023 Mar 11;401(10379):833-842. doi: 10.1016/S0140-6736(22)02465-5. Epub 2023 Feb 16.
5
Projected COVID-19 Mortality Reduction From Paxlovid Rollout.预计帕罗韦德推出后可降低新冠病毒感染死亡率。
JAMA Health Forum. 2023 Mar 3;4(3):e230046. doi: 10.1001/jamahealthforum.2023.0046.
6
First Impressions Matter: Immune Imprinting and Antibody Cross-Reactivity in Influenza and SARS-CoV-2.第一印象很重要:流感和新冠病毒中的免疫印记与抗体交叉反应性
Pathogens. 2023 Jan 21;12(2):169. doi: 10.3390/pathogens12020169.
7
Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments.宿主免疫反应促进接受单克隆抗体治疗的患者中 SARS-CoV-2 突变的发展。
J Clin Invest. 2023 Mar 15;133(6):e166032. doi: 10.1172/JCI166032.
8
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.先前感染 SARS-CoV-2 和混合免疫对奥密克戎变异株和重症疾病的保护效力:系统评价和荟萃回归分析。
Lancet Infect Dis. 2023 May;23(5):556-567. doi: 10.1016/S1473-3099(22)00801-5. Epub 2023 Jan 18.
9
SARS-CoV-2 variant biology: immune escape, transmission and fitness.SARS-CoV-2 变体生物学:免疫逃逸、传播和适应性。
Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18.
10
Long COVID: major findings, mechanisms and recommendations.长新冠:主要发现、机制和建议。
Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13.

与“西班牙流感”相比,诊断方法、治疗手段和疫苗对新冠疫情演变产生了影响吗?

Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with "Spanish Flu"?

作者信息

Lista Florigio, Peragallo Mario Stefano, Biselli Roberto, De Santis Riccardo, Mariotti Sabrina, Nisini Roberto, D'Amelio Raffaele

机构信息

Istituto di Scienze Biomediche della Difesa, Ispettorato Generale della Sanità Militare, Stato Maggiore della Difesa, 00184 Roma, Italy.

Centro Studi e Ricerche di Sanità e Veterinaria, Comando Logistico dell'Esercito, 00184 Roma, Italy.

出版信息

Pathogens. 2023 Jun 23;12(7):868. doi: 10.3390/pathogens12070868.

DOI:10.3390/pathogens12070868
PMID:37513715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10384375/
Abstract

In 1918 many countries, but not Spain, were fighting World War I. Spanish press could report about the diffusion and severity of a new infection without censorship for the first-time, so that this pandemic is commonly defined as "Spanish flu", even though Spain was not its place of origin. "Spanish flu" was one of the deadliest pandemics in history and has been frequently compared with the coronavirus disease (COVID)-19 pandemic. These pandemics share similarities, being both caused by highly variable and transmissible respiratory RNA viruses, and diversity, represented by diagnostics, therapies, and especially vaccines, which were made rapidly available for COVID-19, but not for "Spanish flu". Most comparison studies have been carried out in the first period of COVID-19, when these resources were either not yet available or their use had not long started. Conversely, we wanted to analyze the role that the advanced diagnostics, anti-viral agents, including monoclonal antibodies, and innovative COVID-19 vaccines, may have had in the pandemic containment. Early diagnosis, therapies, and anti-COVID-19 vaccines have markedly reduced the pandemic severity and mortality, thus preventing the collapse of the public health services. However, their influence on the reduction of infections and re-infections, thus on the transition from pandemic to endemic condition, appears to be of minor relevance. The high viral variability of influenza and coronavirus may probably be contained by the development of universal vaccines, which are not easy to be obtained. The only effective weapon still remains the disease prevention, to be achieved with the reduction of promiscuity between the animal reservoirs of these zoonotic diseases and humans.

摘要

1918年,许多国家(但不包括西班牙)正在进行第一次世界大战。西班牙媒体能够首次不受审查地报道一种新感染的传播情况和严重程度,因此这场大流行通常被定义为“西班牙流感”,尽管西班牙并非其起源地。“西班牙流感”是历史上最致命的大流行之一,经常被与冠状病毒病(COVID)-19大流行相比较。这些大流行有相似之处,都是由高度可变且可传播的呼吸道RNA病毒引起的;也有不同之处,体现在诊断、治疗,尤其是疫苗方面,COVID-19很快就有了可用的疫苗,但“西班牙流感”却没有。大多数比较研究是在COVID-19的第一阶段进行的,当时这些资源要么尚未可用,要么使用时间不长。相反,我们想分析先进的诊断方法、抗病毒药物(包括单克隆抗体)以及创新的COVID-19疫苗在疫情控制中可能发挥的作用。早期诊断、治疗和抗COVID-19疫苗显著降低了大流行的严重程度和死亡率,从而防止了公共卫生服务的崩溃。然而,它们对减少感染和再感染的影响,进而对从大流行向地方病状态转变的影响,似乎不太显著。流感和冠状病毒的高病毒变异性可能通过通用疫苗的研发来控制,但通用疫苗并不容易获得。唯一仍然有效的武器仍然是疾病预防,这要通过减少这些人畜共患病的动物宿主与人类之间的混杂来实现。